Peijia Medical (9996.HK), a leading Chinese domestic company inthehigh-growthtranscatheter valve therapeutics and neurovascular interventions markets, announcedthat its TaurusTrio Transcatheter Aortic Valve (TAV) systemreceivedapproval fromthe National Medical Products Administration (NMPA) of China on December 11,2025.The TaurusTrio TAV system is developed and manufactured by PeijiaMedical underan exclusive license from JenaValve Technology, Inc. (JenaValve) for itsTrilogyTranscatheter Heart Valve (THV) System. It is designed to treat patientswithnativesymptomatic severe aortic regurgitation (AR) via transfemoral access. Unlikeinpatients with aortic stenosis, in patients with AR, there is often no calcificationfortheTAV to anchor onto, leaving AR patients with limited treatment options.TheTaurusTrio system incorporates JenaValve's proprietary locator technology,whichenables stable anchoring by engaging the native aortic leaflets evenintheabsenceofcalcium, while ensuring commissural alignment.
The one-year clinical results from the TaurusTrio ALTER-ARstudy demonstratedatechnical success rate of 99.1%, with 0% all-cause mortality at 30 daysandonly2.6%at one year. Patients showed significant cardiac function improvement, with91.7%recovering to NYHA class I/II at six months. The incidence of moderateorgreaterparavalvular leak was 0% at one year, and indicators such as LVEDVandLVMshowed significant reverse remodeling, validating the device's long-termsafetyandefficacy.
The approval of TaurusTrio is a major milestone for Peijia Medical, reflectingitsdedication to structural heart disease innovation, respect for intellectual property,andcommitment to addressing clinical needs. This achievement alsosignifiesakeytechnological breakthrough in China's interventional treatment landscape.Asadedicated device for AR, TaurusTrio offers patients the prospect of longer survival anda better quality of life. With its wider clinical adoption, AR care in Chinawill enteranera of precision, minimally invasive therapy—strengthening patient protectionandexemplifying a collaborative model for domestic medical device innovation.
